ACADIA Pharmaceuticals Inc. (ACAD) and Mersana Therapeutics Inc. (NASDAQ:MRSN) Comparing side by side

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Mersana Therapeutics Inc. (NASDAQ:MRSN) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ACADIA Pharmaceuticals Inc. 26 15.35 N/A -2.09 0.00
Mersana Therapeutics Inc. 5 2.51 N/A -1.55 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of ACADIA Pharmaceuticals Inc. and Mersana Therapeutics Inc.


Table 2 represents ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Mersana Therapeutics Inc. (NASDAQ:MRSN)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals Inc. 0.00% -79.7% -68.1%
Mersana Therapeutics Inc. 0.00% -57.5% -27.9%


ACADIA Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 6.4 and 6.3 respectively. The Current Ratio and Quick Ratio of its competitor Mersana Therapeutics Inc. are 6.2 and 6.2 respectively. ACADIA Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Mersana Therapeutics Inc.

Analyst Recommendations

In next table is given ACADIA Pharmaceuticals Inc. and Mersana Therapeutics Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ACADIA Pharmaceuticals Inc. 0 0 5 3.00
Mersana Therapeutics Inc. 0 0 0 0.00

The consensus price target of ACADIA Pharmaceuticals Inc. is $43, with potential upside of 53.30%.

Insider & Institutional Ownership

The shares of both ACADIA Pharmaceuticals Inc. and Mersana Therapeutics Inc. are owned by institutional investors at 94.9% and 79.4% respectively. About 0.3% of ACADIA Pharmaceuticals Inc.’s share are held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ACADIA Pharmaceuticals Inc. 6.82% -8.69% 3.89% 7.2% 65.97% 52.01%
Mersana Therapeutics Inc. -8.62% -16.47% -30.83% -23.58% -68.89% -14.22%

For the past year ACADIA Pharmaceuticals Inc. has 52.01% stronger performance while Mersana Therapeutics Inc. has -14.22% weaker performance.


On 5 of the 8 factors ACADIA Pharmaceuticals Inc. beats Mersana Therapeutics Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patientsÂ’ lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.